| Literature DB >> 36118081 |
Jing Lin1, Haoyue Ma2, Hang Li2, Jing Han2, Tingting Guo2, Zhen Qin2, Liyan Jia3, Yuehui Zhang3.
Abstract
Recently, with the development of the social economy, the incidence of infertility has increased year by year. With its complex etiology and diversified syndromes, infertility has become one of the most important diseases that plague the physical and mental health of women of childbearing age worldwide. Endometrial factors as an important part affecting female reproductive capacity, due to which induced repeated abortion and multiple uterine cavity operations occur, can destruct endometrium, failing to provide a normal implantation environment for zygote, thus resulting in infertility. Many patients failed to achieve expected results after receiving conventional treatments such as hormone therapy, assisted reproductive technology (ART), granulocyte colony-stimulating factor (G-CSF) therapy, and cell therapy, then turn to complementary and alternative medicine (CAM) therapies for help. Aiming at clarifying the effectiveness and mechanisms of CAM therapy in the treatment of infertility caused by endometrial factors, our paper systematically searched and studied present related literature on the PubMed, CNKI, and other databases, focusing on the aspects of clinical application and mechanism explorations and highlighting the therapeutic effects of Chinese herbal medicine (CHM), acupuncture, and moxibustion on such diseases. Moreover, this paper also introduces the CAM treatments of traditional Chinese medicine (TCM) retention enema, neuromuscular electrical stimulation (NMES), photobiomodulation therapy, dietary intervention, and other measures for infertility caused by endometrial factors, in order to provide a reference for subsequent basic research and clinical work.Entities:
Year: 2022 PMID: 36118081 PMCID: PMC9473886 DOI: 10.1155/2022/4624311
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Summary of a randomized clinical trial of CHM.
| Prescription | Design | Sample size | Interventions | Main outcomes | References |
|---|---|---|---|---|---|
| Gushen Antai pill | RCT | 83 | Treatment group: estradiol valerate + Gushen Antai pill | 1. Total efficiency: treatment group—84.85% (28/33); control group—68.00% (34/50) | [ |
| Control group: estradiol valerate | 2. Endometrial thickness after treatment: treatment group—0.73 ± 0.16 mm; control group—0.88 ± 0.18 mm | ||||
|
| |||||
| Bushen Huoxue recipe | RCT | 60 | Treatment group: estradiol valerate + Bushen Huoxue recipe | 1. Pregnancy rate: treatment group—43.3% (13/30); control group—26.7 (8/30) | [ |
| Control group: estradiol valerate | 2. Endometrial thickness after treatment: treatment group—9.6 ± 1.0 mm; control group—8.2 ± 0.4 mm | ||||
|
| |||||
| Bushen Yanggong decoction | RCT | 120 | Treatment group: Femoston + Bushen Yanggong decoction | 1. Pregnancy rate: treatment group—53.33% (32/60); control group—31.67% (19/60) | [ |
| Control group: Femoston | 2. Endometrial thickness after treatment: treatment group—8.19 ± 0.83 mm; control group—7.17 ± 0.82 mm | ||||
|
| |||||
| Bubao decoction | RCT | 115 | Treatment group: Bubao decoction + aspirin enteric-coated aspirin group | 1. Clinical pregnancy rate: treatment group—47.62%; aspirin group—32.56% | [ |
| Control group | 2. Endometrial thickness after treatment: treatment group—10.65 ±3.03 mm; aspirin group—8.87 ± 2.50 mm | ||||
|
| |||||
| Danyu decoction | RCT | 50 | Treatment group: Danyu decoction | 1. Pregnancy rate: treatment group—60%; control group—28% | [ |
| Control group: vitamin | 2. The rate of type A endometrium: treatment group—84%; control group—68% | ||||
| 3. Treatment group: RI—0.55 ± 0.08; PI—1.83 ± 0.61; control group: RI—0.64 ± 0.16; PI—2.19 ± 0.54 | |||||
|
| |||||
| Jieyuyubao pills | RCT | 107 | Treatment group: Jieyuyubao pills + clomiphene citrate | 1. Pregnancy rate: treatment group—24.07%; control group—11.32% | [ |
| 2. The rate of type A endometrium: treatment group—53.7%; control group—35.8% | |||||
| Control group: clomiphene citrate | 3. Symptom scores: treatment group—2.1 ± 0.6; control group—5.1 ± 0.6 | ||||
|
| |||||
| Erzhi Tiangui granule | RCT | 66 | Treatment group: Erzhi Tiangui granule + gonadotropin therapy | 1. Clinical pregnancy rate: treatment group—54.55% (18/33); control group: 30.30% (10/33) | [ |
| Control group: gonadotropin therapy + placebo granules | 2. Endometrial DNMT1 expression: treatment group—3.31 ± 0.46; control group—2.97 ± 0.49 | ||||
|
| |||||
| Yulin Zhuyun prescription | RCT | 150 | Combine group: Yulin Zhuyun prescription + clomifene citrate capsules | 1. Clinical pregnancy rate: combine group—59.1% (26/44); CHM group—44.2% (19/43); Western medicine group—26.8% (11/41) | [ |
| CHM group: Yulin Zhuyun prescription | 2. Integrin | ||||
| Western medicine group: Clomifene citrate capsules | 3. GLUT4: combine group—146.82 ± 21.84; CHM group—113.64 ± 15.62; Western medicine group—112.92 ± 18.54 | ||||
|
| |||||
| Kuntai capsule | RCT | 71 | Treatment group: Kuntai capsule + clomiphene | 1. Pregnancy rate: treatment group—25% (9/36); control group—11.4% (4/35) | [ |
| Control group: placebo + clomiphene | 2. Integrin | ||||
|
| |||||
| Wenjing Quyu prescription | RCT | 72 | Treatment group: Wenjing Quyu prescription + Gn + HCG | 1. Pregnancy rate: treatment group—59.38% (19/32); control group—12.96% (7/24) | [ |
| Control group: Gn + HCG | 2. Covered pinopode area: treatment group—>50%; control group—<20% | ||||
|
| |||||
| Huayu Xiaozheng prescription | RCT | 60 | Treatment group: Huayu Xiaozheng prescription + urofollicle-stimulating hormone + chorionic gonadotropin + letrozole | 1. Pregnancy rate: treatment group—60% (18/30); control group—33.33% (10/30) | [ |
| Control group: urofollicle-stimulating hormone + chorionic gonadotropin + letrozole | 2. Uterine volume: treatment group—100.27 ± 2.13 cm3; control group—102.47 ± 3.90 cm3 | ||||
| 3. Endometrial thickness after treatment: treatment group—9.89 ± 044 mm; control group—8.04 ± 1.28 mm | |||||
|
| |||||
| Yishen Sanjie Quyu decoction | RCT | 102 | Treatment group: Yishen Sanjie Quyu decoction | 1. Uterine volume: treatment group—95.46 ± 3.21 cm3; control group—105.44 ± 4.23 cm3 | [ |
| Control group: Sanjie Zhentong capsule | 2. Symptom scores: treatment group—5.34 ± 1.46; control group—11.21 ± 2.01 | ||||
|
| |||||
| Wenjing Yangxue decoction | RCT | 70 | Treatment group: Wenjing Yangxue decoction + dydrogesterone tablets + moxibustion | 1. Uterine volume: treatment group—136.47 ± 23.71 cm3; control group—152.38 ± 39.67 cm3 | [ |
| Control group: dydrogesterone tablets + moxibustion | 2. RI : treatment group—0.63 ± 0.07; control group—0.66 ± 0.05 | ||||
|
| |||||
| Penning granules | RCT | 58 | Treatment group: Penning granules | 1. Pregnancy rate: treatment group—54.55% (18/33); control group—20% (1/25) | [ |
| Control group: levofloxacin + metronidazole tablets | 2. CD38 : treatment group—8.89 ± 7.45; control group—20.12 ± 12.35 | ||||
| 3. HIF-1 | |||||
Summary of basic studies of CHM.
| Prescription | Experimental type | Sample size | Interventions | Main outcomes | References |
|---|---|---|---|---|---|
| Dingkun pill | CD1 mice | 57 | Dingkun pill (DK) group | 1. Embryo implantation rate (at 22:00 on D4) : DK-treated group—69% (20/29); control group—28.6% (8/28) | [ |
| 2. Relative mRNA level: estrogen-target epithelial genes (Lif, Ltf) and stromal genes (Igf1, Spon2) were more induced in the DK group compared with the control | |||||
|
| |||||
| Ankun Zhongzi Wan | Kunming mice | 60 | Ankun Zhongzi Wan (AZW) group | 1. Pregnancy rate: AZM group—75% (15/20); model group—35% (7/20) | [ |
| Model group | 2. ER : AZM group—10.55 ± 5.23; model group—4.31 ± 2.39 | ||||
| Normal group | 3. PR : AZM group—8.73 ± 1.16; model group—2.91 ± 0.78 | ||||
|
| |||||
| Bushen Yiqi Huoxue recipe | Wistar rats | 60 | Bushen Yiqi Huoxue recipe (BYHR) group | 1. Pregnancy rate: BYHR group—66.67%; model group—45.45% | [ |
| Progesterone group | 2. P : BYHR group—118.98 ± 10.77; model group—73.62 ± 10.24 | ||||
| Model group | 3. PR : BYHR group—0.23 ± 0.025; model group—0.14 ± 0.022 | ||||
|
| |||||
| Tiaojing Zhuyun capsule | Kunming mice | 48 | Tiaojing Zhuyun capsule (TZC) group | 1. E2 : TZC group—4.67 ± 1.25; model group—1.33 ± 0.80 | [ |
| 2. P : TZC group—102.15 ± 45.74; model group—50.18 ± 31.57 | |||||
| 3. ER : TZC group–11.62 ± 3.74; model group—5.26 ± 2.11 | |||||
| 4. PR : TZC group—8.07 ± 1.22; model group—2.76 ± 0.84 | |||||
|
| |||||
| Zhuyun I recipe | SD rats | 70 | Zhuyun I recipe (ZIR) group (7.3 g/kg, 14.6 g/kg) | 1. E2 : ZIR group—21.8 ± 2.73(14.6 g/kg); 19.48 ± 6.05(7.3 g/kg); model group—11.00 ± 3.26 | [ |
| 2. P : ZIR group—75.41 ± 19.42(14.6 g/kg); 61.80 ± 14.19(7.3 g/kg); model group—39.88 ± 2.83 | |||||
|
| |||||
| Bushen Tiaoxue granules | SD rats | 113 | Controlled ovarian hyperstimulation (COH) model group | 1. Pregnancy rate: COH + BTG (0.82 g/kg)—80% (8/10); COH + BTG (1.64 g/kg)—70% (14/20); COH + BTG (3.27 g/kg)—80% (12/15); COH + KW (0.46 g/kg)—92.9% (13/14); COH + KW (0.91 g/kg)—80% (12/15); COH + KW (1.82 g/kg)—80% (8/15) | [ |
| Kunling Wan | 2. Markers of blood vessels: the fluorescence intensity and the number of VEGFA and CD31‐positive vessels decreased in the COH group, while BTG and KW induced vascularization noticeably compared with the COH group. | ||||
|
| |||||
| Bushen Huoxue recipe | Kunming mice | 146 | Control group | 1. Pregnancy rate: BSHXR group (5.7 g/kg)—53.33% (10/27); BSHXR group (11.4 g/kg)—57.86% (19/28); BSHXR group (22.8 g/kg)—53.85% (7/13) | [ |
| 2. Markers of blood vessels: HIF1 | |||||
| Xiaoyao powder | Kunming mice | 78 | Controlled group | Pregnancy rate: XYP + COH groups—65% (13/20); COH group—40% (8/20); controlled group—85% (17/20) | [ |
|
| |||||
| Tiaojing Cuyun recipe | Kunming mice | 120 | Control group | 1. The number of implantation sites: Control group—15; EID group—2; TJCYR + EID (12 g/kg)—2; TJCYR + EID (24 g/kg)—10; TJCYR + EID (48 g/kg)—12 | [ |
| 2. Pinopodes were well-developed; they were sparse; and they in this group improved significantly following treatment with TJCYR. | |||||
|
| |||||
| Wenshen Yangxue decoction | Wistar rats | 100 | Control group | 1. Implantation rate: control group—100%; model group—40%; WSYX D (1.3/100g)—40%; WSYXD (2.6/100 g)—50%; WSYSD (2.6/100 g)—70% | [ |
| 2. Control and high groups: a large number of pinopodes but little short microvilli on the endometrial surface; middle group: pinopodes existed in only parts of endometrium; low groups: no pinopode, but numerous microvilli can be found | |||||
|
| |||||
| Zhuyun recipe | Kunming mice | 139 | Control group | 1. Pregnancy rate: control group—83.33%; OS model group—6.67%; OS + ZYR group—54.55%; EID model group—18.75%; EID + ZYR group—65.22% | [ |
| 2. OS and EID model group: a moderate number of pinopodes without microvilli; | |||||
|
| |||||
| Yiqixue Buganshen recipe | Kunming mice | 180 | Control group | 1. Blastocyst implantation: control group—13.70 ± 0.67; | [ |
| 2. Integrin | |||||
|
| |||||
| Tokishakuyakusan | Wistar rats | Not clear | Tokishakuyakusan (TSS) group | 1. The number of Implantation: 1% TSS group—11.4 ± 1.4; 3% TSS group—14.7 ± 0.8; model group—9.0 ± 2.1 | [ |
| 2. LIF mRNA levels: model group—0.42 ± 0.05; 3%TSS group—2.40 ± 0.93 | |||||
|
| |||||
| Zishen Yutai pills | SD rats | 90 | Normal group, control group | 1. Pregnancy rate: control group—40%; ZYP group—70% | [ |
| 2. The mRNA and protein expression levels of LIF in the ZYP group were significantly higher than those in the control group | |||||
|
| |||||
| Modified Shoutaiwai recipe | Kunming mice | 70 | Modified Shoutaiwai recipe (MSTW) group | 1. Expression of integrin | [ |
| 2. Expression of LIF mRNA : MSTW group—0.9835 ± 0.0059; aspirin group—0.9793 ± 0.0061; control group—0.9670 ± 0.0103 | |||||
|
| |||||
| Qiu's Neiyi recipe | ICR mice | 45 | Model group, danazol group | 1. Qiu suppressed the expression of IL-1 | [ |
| 2. The expression of these proteins was significantly decreased after being treated with qiu and danazol ( | |||||
|
| |||||
| Modified Danggui Shaoyao powder | SD rats | 60 | Blank group | 1. NF- | [ |
| 2. TGF- | |||||
|
| |||||
| Shaofu Zhuyu decoction | SD rats | 46 | Control group | Embryo implantation rate: model group—33.33%; estradiol valerate group—55.56%; SZD group (144 mg/kg)—44.44%; SZD group (288 mg/kg)—88.89% | [ |
|
| |||||
| Bushen Tiaochong decoction | SD rats | 60 | Normal control group; model group; estradiol valerate group; Bushen Tiaochong decoction group (8.525 g/kg, 17.05 g/kg, 34.10 g/kg) | Compared with the model group, the endometrium of each administration group,caspase-1, IL-1 | [ |
Summary of a randomized clinical trial of acupuncture.
| References | Design | Sample size | Interventions | Main outcomes | Acupuncture points |
|---|---|---|---|---|---|
| [ | RCT | 60 | Treatment group: acupuncture + TCM | 1. Total efficiency: treatment group—26.7% (8/30); control group—6.7% (2/30) | Guanyuan (RN4), Sanyinjiao (SP6) |
|
| |||||
| [ | RCT | 60 | Treatment group: acupuncture + letrozole tablets | 1. Total efficiency: treatment group—66.7% (20/30); control group—40.0% (12/30) | Baihui (DU20), Mingmen (DU4) |
|
| |||||
| [ | Single-blind | 60 | Treatment group: acupuncture + estradiol valerate tablets | 1. Total efficiency: treatment group—63.33% (19/30); control group—33.33% (10/30) | Zhongwan (RN12), Tianshu (ST25) |
|
| |||||
| [ | RCT | 90 | Treatment group: acupuncture + TCM + aspirin enteric-coated tablets | Endometrial thickness after treatment: treatment group—10.59 ± 2.25 mm; control group—5.39 ± 1.00 mm | Pishu (BL20), Shenshu (BL23) |
|
| |||||
| [ | RCT | 126 | Treatment group: acupuncture + moxibustion + TCM + estradiol valerate tablets + progesterone capsules | 1. Total efficiency: treatment group—47.6% (30/63); control group—28.6% (18/63) | Guanyuan (RN4), Taixi (KI3) |
|
| |||||
| [ | RCT | 72 | Treatment group: acupuncture + warm group acupuncture + EA + estradiol valerate tablets | 1. Total efficiency: treatment group—50.0% (18/36); control group—33.3% (12/36) | Gongsun (SP4) |
|
| |||||
| [ | RCT | 74 | Treatment group: Tongyuan acupuncture + estradiol valerate tablets | 1. Total efficiency: treatment group—37.8% (14/37); control group—16.2% (6/37) | Qiangjian (DU18), Naohu (DU17) |
|
| |||||
| [ | Double-blind RCT | 120 | Treatment group 1: acupuncture test | Total efficiency: treatment group 1—58.69% (27/46) | Treatment group1: Guanyuan (RN4), Zhongji (RN3) |
|
| |||||
| [ | RCT | 64 | Treatment group: EA intervention | 1. Total efficiency: treatment group—50.00% (15/30); control group—41.94% (13/31) | Baihui (DU20), Zhongwan (RN12) |
|
| |||||
| [ | RCT | 80 | Treatment group: EA + clomiphene citrate tablets | 1. Total efficiency: treatment group—21.1% (8/38); control group—16.2% (6/37) | Qihai (RN6), Guanyuan (RN4) |
|
| |||||
| [ | RCT | 80 | Treatment group: TCM + EA + aspirin enteric-coated tablets | 1. Total efficiency: treatment group—40.0% (16/40); control group—27.5% (11/40) | Guanyuan (RN4), Zigong (EX-CA1) |
Summary of basic studies of the acupuncture and moxibustion.
| References | Animal type | Sample size | Interventions | Main outcomes | Acupuncture points |
|---|---|---|---|---|---|
| [ | Wistar rats | 60 | Normal group | 1. Implantation rate: normal group—95% (19/20); model group—45% (9/20); acupuncture group—75% (15/20) | Zusanli (ST36), Sanyinjiao (SP6) |
|
| |||||
| [ | SD rats | Not clear | PCOS model group | 1. Endometrial thickness: model group—30 ± 21 | Guanyuan (RN4), Zhongji (RN3) |
|
| |||||
| [ | Wistar rats | 40 | Normal group (N) | 1. Pregnancy rate: N group—100% (10/10); M group—40% (4/10); A group—70% (7/10); C group—40% (4/10) | Zusanli (ST36), Sanyinjiao (SP6) |
|
| |||||
| [ | C57BL6 mice | 50 | Blank control group | 1. The endometrial thickness significantly increased in the EBZYD, acupuncture, and EBZYD combined with the acupuncture group compared with the model group. | Guanyuan (RN4), Sanyinjiao (SP6) |
|
| |||||
| [ | SD rats | 40 | Control group | The amount of ER and PR in the BMSC group and the combined group was significantly higher than that in the model group. | Guanyuan (RN4), Zigong (EX-CA1) |
|
| |||||
| [ | SD rats | 70 | Normal group (G) | 1. Endometrial thickness: G—92 ± 25 | Guanyuan (RN4) |
|
| |||||
| [ | Adult Sprague Dawley rats | 60 | Control group | 1. Pregnancy rate: control group—100% (20/20); thin endometrium model group—20% (4/20); EA group—100% (20/20) | Sanyinjiao (SP6) Zigong (EX-CA1) |
|
| |||||
| [ | SD rats | 80 | Normal treatment group | 1. The results showed that the thickness of endometrium in the LF-EA group and the HF-EA group was significantly higher than that in the model group. | Guanyuan (RN4) |
|
| |||||
| [ | Kunming mice | 60 | Natural cycle group (NC) | After EA treatment, the expression of IGF-1 protein and its mRNA protein in mouse endometrium increased. | Guanyuan (RN4) |
|
| |||||
| [ | SD rats | 40 | Normal group | 1. Endometrial thickness: normal group > wheat grain moxibustion group > estrogen group > endometrial model group | Shenshu (BL23) |
Summary of a randomized clinical trial of moxibustion.
| References | Design | Sample size | Interventions | Main outcomes | Acupuncture points |
|---|---|---|---|---|---|
| [ | RCT | 92 | Treatment group: warm acupuncture | 1. Pregnancy rate: treatment group—34.78% (16/50); control group—13.04% (6/50) | Guanyuan (RN4), Zigong (EX-CA1) |
|
| |||||
| [ | RCT | 136 | Treatment group: warm acupuncture + Zhen qi decoction | 1. Pregnancy rate: treatment group—63.24% (43/68); control group—41.18% (28/68) | Guanyuan (RN4), Zhongji (RN3) |
|
| |||||
| [ | RCT | 56 | Treatment group: warm acupuncture | 1. Clinical pregnancy rate: treatment group—46.3%; control group—20.7% | Zhongwan (RN12), Tianshu (ST25) |
|
| |||||
| [ | RCT | 60 | Treatment group: thunder fire moxibustion | Pregnancy rate: treatment group—50.00% (15/30); control group—23.30% (7/30) | Guanyuan (RN4), Qihai (RN6) |
|
| |||||
| [ | RCT | 100 | Treatment group: estradiol valerate and thunder fire moxibustion | 1. Pregnancy rate: treatment group—40.00% (20/50); control group—20.00% (10/50) | Shenque (RN8), Guanyuan (RN4) |
|
| |||||
| [ | Retrospective study | 60 | Treatment group: wheat moxibustion | 1. Pregnancy rate: treatment group—33.33% (10/30); control group—23.33% (7/30) | Qihai (RN6), Guanyuan (RN4) |
|
| |||||
| [ | RCT | 80 | Treatment group: conventional acupuncture and wheat grain moxibustion | 1. Total efficiency: treatment group—97.5% (39/40); control group—82.5% (33/40) | Guanyuan (RN4), Zigong (EX-CA1) |
|
| |||||
| [ | RCT | 70 | Treatment group: EA + ginger moxibustion isolation | 1. Pregnancy rate: treatment group—56.25% (18/32); control group—30.3% (10/32) | Zigong (EX-CA1), Guilai (ST29) |
|
| |||||
| [ | RCT | 80 | Treatment group: invigorating qi-tonifying kidney Chinese medicine + Ren Mai moxibustion | 1. Pregnancy rate: treatment group—67.5% (27/40); control group—42.5% (17/40) | Shenque (RN8), Qugu (RN2) |
|
| |||||
| [ | RCT | 210 | Treatment group 1: heat-sensitive moxibustion + acupoint injection | Endometrial thickness after treatment: treatment group 1—10.0 ± 0.98 mm; treatment group 2—9.24 ± 0.87 mm; control group—7.89 ± 1.02 mm | Yaoyangguan (DU3) |